[New post] Molnupiravir

SupremeCmdr posted: " A planned interim analysis of 775 patients in Merck's study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir gro" Respond to this post by replying above this line New post on lifeunderwriter.net Molnupiravir by SupremeCmdr A planned interim analysis of 775 patients in Merck's study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients. Merck to Seek FDA OK for Its COVID Pill After Trial Stopped Early -- https://www.medscape.com/viewarticle/960089?src=rss#vp_2 This free site is ad-supported. Learn more ​ SupremeCmdr | October 2, 2021 at 1:03 am | Tags: COVID-19, Merck, Molnupiravir, pharmaceutical | Categories: COVID-19, Infectious Diseases, Pharma | URL: https://wp.me/pbjZp-3oR Comment    See all comments    Like Unsubscribe to no longer receive posts from lifeunderwriter.net. Change your email settings at Manage Subscriptions. Trouble clicking? Copy and paste this URL into your browser: http://lifeunderwriter.net/2021/10/02/molnupiravir/ Thanks for flying with WordPress.com